Alosita Met (50/500mg) 14 Tablets
Alogliptin and metformin 50/500mg for type 2 diabetes.
Alosita Met (50/500mg) combines alogliptin (a DPP-4 inhibitor) and metformin for type 2 diabetes. Alogliptin enhances glucose-dependent insulin secretion; metformin reduces hepatic glucose production and improves insulin sensitivity. Used when dual therapy is needed for glycaemic control.
Purpose
Treatment of type 2 diabetes mellitus as adjunct to diet and exercise when dual therapy is appropriate.
Ingredients
Alogliptin 50mg and metformin hydrochloride 500mg per tablet.
Warnings
Contraindicated in severe renal impairment and diabetic ketoacidosis. Risk of lactic acidosis with metformin. Not for type 1 diabetes.
Side Effects
Nausea, diarrhoea, abdominal discomfort, hypoglycaemia when combined with insulin or sulphonylurea. Rare: pancreatitis. Report severe abdominal pain.
Storage Instructions
Store below 30°C in a dry place. Keep in original pack; protect from moisture.
| Brand | Saffron Pharmaceuticals (PVT.) LTD. |
| Status | Active |
Related Products
